Back to mobile site

Roth Capital Resumes Intec Pharma Ltd. (NTEC) at Buy

June 26, 2018 7:55 AM EDT Send to a Friend
Roth Capital resumes coverage on Intec Pharma Ltd. (NASDAQ: NTEC) with a Buy rating and a price target of $10.00.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login